2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/12hpyu88k-1qt.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/22x_afbr-hdp6.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T6aa8,

Summary Table

Category	Details
Risk Factors	African American women aged 20 to 40 years; Northern European (Scandinavian) descent; nonsmokers (paradoxically); family history of sarcoidosis
Etiology	Unknown. Believed to be an exaggerated CD4+ Th1 immune response to an unidentified antigen in genetically susceptible individuals
Patient Presentation	Dry cough, progressive dyspnea, fatigue, malaise, fever, weight loss. May present with painfully tender red nodules on shins (erythema nodosum) or eye redness and pain
Classic Physical Exam	Bilateral hilar lymphadenopathy on imaging; erythema nodosum; lupus pernio (violaceous plaques on nose, cheeks, ears); anterior uveitis; hepatosplenomegaly; parotid gland enlargement
Key Diagnostic Results	Chest X-ray: bilateral hilar lymphadenopathy. Labs: elevated serum ACE, hypercalcemia, elevated 1,25-dihydroxyvitamin D. Biopsy: noncaseating granulomas. PFTs: restrictive pattern with decreased DLCO
Management	Observation for mild or asymptomatic disease. Systemic corticosteroids (prednisone) for significant organ involvement. Methotrexate or azathioprine as steroid-sparing agents
Keywords	"Noncaseating granulomas," "bilateral hilar lymphadenopathy," "elevated ACE," "hypercalcemia," "erythema nodosum," "lupus pernio," "young African American woman," "Schaumann bodies," "asteroid bodies"

1. Pathophysiology

Sarcoidosis is a systemic inflammatory disease driven by an exaggerated CD4+ T-helper type 1 (Th1) immune response. The current understanding is that an unidentified antigen, possibly environmental, microbial, or self-derived, triggers a disproportionate immune reaction in genetically predisposed individuals. The activated CD4+ T cells release interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), which recruit and activate macrophages at the site of inflammation.

These activated macrophages transform into epithelioid cells and fuse to form multinucleated giant cells. The end result is the formation of well-organized, tightly packed collections of immune cells known as noncaseating granulomas. The term "noncaseating" is critical because it distinguishes sarcoidosis from tuberculosis and fungal infections, which produce caseating (centrally necrotic) granulomas. On biopsy, these granulomas may contain Schaumann bodies (laminated calcium and protein inclusions) and asteroid bodies (star-shaped inclusions within giant cells), both of which are suggestive but not pathognomonic.

A frequently tested consequence of granuloma formation is hypercalcemia. The macrophages within the granulomas express 1-alpha-hydroxylase, an enzyme that converts 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D (calcitriol). This ectopic, unregulated production of calcitriol increases intestinal calcium absorption, leading to hypercalcemia and hypercalciuria. This is the same enzyme found in the kidney, but in sarcoidosis, its activity is independent of PTH regulation. The resulting hypercalcemia can cause nephrolithiasis, nephrocalcinosis, and if severe, renal failure.

The epithelioid cells and macrophages within the granulomas also produce angiotensin-converting enzyme (ACE). While elevated serum ACE is a classic laboratory finding in sarcoidosis, it is neither sensitive nor confirmatory on its own. It is better used for monitoring disease activity over time rather than for initial diagnosis.

Because sarcoidosis is a systemic disease, granulomas can deposit in virtually any organ, which explains the wide variety of presentations. The lungs and hilar lymph nodes are most commonly involved (over 90% of cases), but the skin, eyes, liver, spleen, heart, nervous system, and musculoskeletal system can all be affected. The reason the disease often resolves spontaneously, particularly in early stages, is that the granulomatous inflammation can self-limit once the immune stimulus diminishes. However, in some patients, chronic inflammation leads to irreversible fibrosis.

2. Classification and Clinical Manifestation

Scadding Radiographic Staging (Chest X-Ray)

This classification is one of the most testable aspects of sarcoidosis. It predicts prognosis and likelihood of spontaneous resolution.

Stage	Chest X-Ray Finding	Spontaneous Resolution Rate
Stage 0	Normal chest radiograph	N/A
Stage I	Bilateral hilar lymphadenopathy (BHL) alone	~60 to 80%
Stage II	BHL with pulmonary infiltrates	~50 to 60%
Stage III	Pulmonary infiltrates without BHL	~30%
Stage IV	Pulmonary fibrosis (irreversible)	0% (irreversible damage)

The key teaching point is that the higher the stage, the lower the chance of spontaneous remission. Stage I has an excellent prognosis and most patients never need treatment. Stage IV represents end-stage fibrotic disease.

Named Clinical Syndromes

Syndrome	Clinical Features	Prognosis
Lofgren Syndrome	Bilateral hilar lymphadenopathy + erythema nodosum + fever + migratory polyarthralgia (commonly ankles)	Excellent; usually self-limited
Heerfordt Syndrome (Uveoparotid Fever)	Anterior uveitis + parotid gland enlargement + facial nerve palsy (CN VII) + fever	Variable
Mikulicz Syndrome	Bilateral painless swelling of lacrimal and salivary glands	Variable

Organ-by-Organ Manifestations

System	Manifestations
Pulmonary	Dry cough, dyspnea, bilateral hilar lymphadenopathy, restrictive lung disease, pulmonary fibrosis
Skin	Erythema nodosum (tender red nodules on anterior shins); lupus pernio (violaceous indurated plaques on nose, cheeks, ears); papules, plaques, scar infiltration
Eyes	Anterior uveitis (most common ocular finding); lacrimal gland enlargement; keratoconjunctivitis sicca
Liver	Hepatic granulomas (common histologically); elevated alkaline phosphatase; rarely causes clinical hepatitis
Cardiac	Conduction abnormalities (heart block, bundle branch block); arrhythmias; dilated cardiomyopathy; sudden cardiac death
Neurologic	Cranial nerve palsies (CN VII most common); hypothalamic/pituitary dysfunction (diabetes insipidus); aseptic meningitis; peripheral neuropathy
Musculoskeletal	Polyarthralgia (especially ankles); Dactylitis; bone cysts
Renal	Nephrolithiasis and nephrocalcinosis secondary to hypercalciuria
Hematologic	Lymphopenia (peripheral blood); elevated CD4/CD8 ratio in BAL fluid; splenomegaly; anemia of chronic disease
Endocrine	Hypercalcemia; hypercalciuria; rarely central diabetes insipidus from hypothalamic infiltration

3. Diagnostic Workup

Test	Role	Expected Finding
Chest X-ray	Best initial test	Bilateral hilar lymphadenopathy (with or without parenchymal infiltrates)
CT Chest (High-Resolution)	Better anatomic characterization	Perilymphatic nodules, bilateral hilar and mediastinal lymphadenopathy, upper lobe predominance
Tissue Biopsy	Gold standard / most accurate test	Noncaseating granulomas with multinucleated giant cells; no caseation, no organisms on special stains
Serum ACE	Supportive (not diagnostic)	Elevated; useful for monitoring disease activity rather than confirming diagnosis
Serum Calcium	Screening for complications	Hypercalcemia
24-Hour Urine Calcium	Assess renal calcium load	Hypercalciuria
1,25-Dihydroxyvitamin D	Confirms mechanism of hypercalcemia	Elevated (ectopic production by granulomas)
PFTs	Assess pulmonary function	Restrictive pattern (decreased FVC, decreased TLC); decreased DLCO
Bronchoalveolar Lavage (BAL)	Supportive	Elevated CD4/CD8 ratio (typically >3.5:1); lymphocytic alveolitis
ECG / Cardiac MRI	Screen for cardiac involvement	Conduction abnormalities; late gadolinium enhancement on MRI
PET Scan (FDG-PET)	Identify active disease / occult involvement	Increased FDG uptake in affected organs

The diagnostic process for sarcoidosis begins with the clinical presentation and imaging. When a young patient, particularly an African American woman in her 20s to 30s, presents with cough, dyspnea, and a chest X-ray showing bilateral hilar lymphadenopathy, sarcoidosis should be at the top of the differential. The chest X-ray is the best initial test because it is readily available and demonstrates the hallmark finding in most patients.

However, bilateral hilar lymphadenopathy is not exclusive to sarcoidosis. Lymphoma and infections can produce a similar appearance. For this reason, the diagnosis requires histologic confirmation. A tissue biopsy demonstrating noncaseating granulomas is the gold standard. The most commonly biopsied sites include the lung (via transbronchial biopsy during bronchoscopy), skin lesions, and peripheral lymph nodes. It is essential that the biopsy specimen is also sent for AFB stain, fungal stain, and culture to exclude tuberculosis and fungal infections, because those conditions produce granulomas as well but with caseation and identifiable organisms.

Serum ACE is frequently ordered but should not be used to confirm or exclude the diagnosis. It has poor sensitivity (around 60%) and poor specificity (elevated in other granulomatous diseases). Its primary utility is in tracking disease activity in patients with established sarcoidosis. A rising ACE level may suggest disease flare, while a falling level may indicate treatment response.

Serum calcium and 24-hour urine calcium should be checked in all patients because hypercalcemia and hypercalciuria are treatable complications. If hypercalcemia is found, a 1,25-dihydroxyvitamin D level will be elevated, confirming the ectopic calcitriol production by granulomas. Note that the PTH level will be suppressed (not elevated), which distinguishes this from primary hyperparathyroidism.

Pulmonary function tests typically show a restrictive pattern with reduced FVC and TLC, along with a decreased DLCO reflecting impaired gas exchange due to granulomatous inflammation of the interstitium. In some cases, particularly with endobronchial disease, an obstructive pattern may coexist.

Bronchoalveolar lavage showing a CD4-to-CD8 ratio greater than 3.5:1 is supportive of the diagnosis, though not confirmatory on its own. This reflects the Th1 lymphocyte predominance in the alveolar space.

All patients with sarcoidosis should undergo an ECG at baseline to screen for cardiac involvement, which can present insidiously with heart block or arrhythmias. Cardiac MRI with late gadolinium enhancement is used when cardiac sarcoidosis is suspected and can reveal myocardial granulomatous infiltration.

4. Management and Treatment

Clinical Scenario	Treatment
Asymptomatic or mild disease (Stage I)	Observation only. No treatment required. High rate of spontaneous resolution
Erythema nodosum / mild arthralgia	NSAIDs for symptom control
Significant pulmonary symptoms (Stage II to III with declining PFTs)	Prednisone 20 to 40 mg/day for 4 to 6 weeks, then taper over 6 to 12 months
Anterior uveitis	Topical corticosteroid eye drops (e.g., prednisolone acetate). Systemic steroids if refractory
Cardiac sarcoidosis	Systemic corticosteroids. May require pacemaker or ICD for conduction disease or arrhythmia
Neurosarcoidosis	High-dose systemic corticosteroids. Steroid-sparing agents early (methotrexate, azathioprine)
Hypercalcemia	Systemic corticosteroids (inhibit granuloma 1-alpha-hydroxylase activity); hydration
Steroid-refractory or chronic relapsing disease	Methotrexate, azathioprine, or mycophenolate as steroid-sparing agents
Refractory to conventional immunosuppression	Anti-TNF-alpha therapy: infliximab
Skin-predominant disease	Hydroxychloroquine
Stage IV (pulmonary fibrosis, end-stage)	Lung transplantation evaluation

The cornerstone principle for exam purposes is that not all patients with sarcoidosis require treatment. Many cases, particularly Stage I, resolve spontaneously within 12 to 24 months. Treatment is indicated when there is significant organ dysfunction, progressive symptoms, or dangerous extrapulmonary involvement (cardiac, neurologic, ocular disease unresponsive to topical therapy, or symptomatic hypercalcemia).

When treatment is indicated, systemic corticosteroids are first-line. The typical regimen is prednisone 20 to 40 mg daily for an initial period of 4 to 6 weeks. If the patient responds, the dose is gradually tapered over 6 to 12 months. Abrupt discontinuation should be avoided because relapse rates are high. Some guidelines suggest a total treatment duration of at least 12 months for pulmonary sarcoidosis.

For patients who cannot tolerate long-term corticosteroids due to side effects (weight gain, diabetes, osteoporosis, adrenal suppression) or who relapse upon tapering, steroid-sparing agents are introduced. Methotrexate is the most commonly used second-line agent, typically dosed at 10 to 15 mg per week with concurrent folic acid supplementation. Azathioprine and mycophenolate mofetil are alternatives.

Hydroxychloroquine has a role primarily in skin-predominant sarcoidosis and hypercalcemia, though it is less potent than corticosteroids for pulmonary disease.

For truly refractory cases, infliximab (an anti-TNF-alpha monoclonal antibody) has demonstrated efficacy. This is because TNF-alpha is a central cytokine in granuloma formation and maintenance, making it a logical therapeutic target.

Corticosteroids effectively treat hypercalcemia in sarcoidosis by directly inhibiting the 1-alpha-hydroxylase enzyme in granulomas, reducing calcitriol production. This is a highly testable point, as it differs from the management of hypercalcemia in malignancy or hyperparathyroidism.

Cardiac sarcoidosis and neurosarcoidosis warrant aggressive immunosuppression from the outset, and device therapy (pacemaker, implantable cardioverter-defibrillator) should be considered when conduction abnormalities or life-threatening arrhythmias are present.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Tuberculosis	Both produce granulomas; both can cause hilar lymphadenopathy, cough, weight loss, and fever	TB granulomas are caseating (central necrosis). AFB stain and culture will be positive. Sarcoidosis granulomas are noncaseating, and stains for organisms are negative
Lymphoma (especially Hodgkin)	Both cause bilateral hilar and mediastinal lymphadenopathy in young adults	Lymphoma presents with B-symptoms (drenching night sweats, significant weight loss) and biopsy shows Reed-Sternberg cells, not granulomas
Berylliosis	Histologically identical noncaseating granulomas; similar chest X-ray findings and restrictive PFTs	Occupational exposure to beryllium (aerospace, electronics, ceramics). Positive beryllium lymphocyte proliferation test (BeLPT) distinguishes it
Hypersensitivity Pneumonitis	Granulomas on biopsy; restrictive lung disease; dyspnea	Granulomas in HP are loosely formed and poorly organized. There is a clear history of antigen exposure (birds, mold, hay). BAL shows predominant CD8+ lymphocytes (low CD4/CD8 ratio), opposite of sarcoidosis
Histoplasmosis / Coccidioidomycosis	Granulomatous inflammation; hilar lymphadenopathy; may mimic sarcoidosis on imaging	Geographic exposure history (Ohio/Mississippi River valley for histoplasmosis; Southwestern US for coccidioidomycosis). Fungal stains and cultures are positive. Granulomas may caseate
Primary Hyperparathyroidism	Both cause hypercalcemia	In PHPT, PTH is elevated and 1,25-dihydroxyvitamin D is normal or low. In sarcoidosis, PTH is suppressed and 1,25-dihydroxyvitamin D is elevated
IgG4-Related Disease	Multisystem disease with lymphadenopathy, salivary/lacrimal gland involvement, and organ fibrosis	Biopsy shows dense lymphoplasmacytic infiltrate with storiform fibrosis, not noncaseating granulomas. Elevated serum IgG4

6. Traps and High-Yield Pearls

The single most common way students answer sarcoidosis questions incorrectly is by confusing noncaseating granulomas with caseating granulomas. When a vignette describes a young patient with bilateral hilar lymphadenopathy and a biopsy showing noncaseating granulomas, the answer is sarcoidosis. The moment "caseating" or "central necrosis" appears, the diagnosis shifts to tuberculosis or a fungal infection. This distinction must be automatic.

A second trap involves the mechanism of hypercalcemia. Students often select primary hyperparathyroidism as the cause of elevated calcium in a sarcoidosis patient. The differentiator is straightforward: in sarcoidosis, PTH is suppressed (because the hypercalcemia is driven by excess 1,25-dihydroxyvitamin D from granulomas, not by parathyroid hormone). If the question provides both a calcium level and a PTH level, check the PTH first.

A third common error is initiating corticosteroid therapy for every patient diagnosed with sarcoidosis. Exam questions frequently test the concept that Stage I sarcoidosis with bilateral hilar lymphadenopathy alone, in an asymptomatic patient, requires observation only. Treatment is reserved for patients with progressive or organ-threatening disease.

Students also miss the connection between sarcoidosis and erythema nodosum. When a vignette describes a young woman with bilateral ankle pain, tender red nodules on the shins, and bilateral hilar lymphadenopathy, this is Lofgren syndrome. This specific combination carries an excellent prognosis and is a classic "pattern recognition" question.

Finally, be alert for the cardiac and neurologic complications. If a patient with known sarcoidosis develops a new heart block (especially third-degree AV block in a young person), the question is testing your recognition of cardiac sarcoidosis. Similarly, unilateral or bilateral facial nerve palsy in the setting of hilar lymphadenopathy should trigger consideration of neurosarcoidosis (or the complete Heerfordt syndrome if parotid swelling and uveitis are also present).

The core competency being tested across all sarcoidosis questions is pattern recognition of the classic demographic, imaging findings, and histopathologic features, combined with the ability to distinguish it from infectious granulomatous diseases and to apply the correct management threshold.

1e:["$","$L2d",null,{"article":{"id":"ef8132b4-e8ea-443b-af48-a458a0fec6ae","title":"Sarkoidosis","content":"$2e","category":"Respirologi","created_at":"2026-07-06T07:21:19.930445+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]